Onivyde pegylated liposomal (previously Onivyde)

<p>Onivyde pegylated liposomal is a cancer medicine used in adults to treat a form of pancreatic cancer called metastatic adenocarcinoma of the pancreas. Metastatic means that the cancer has spread to other parts of the body. Onivyde pegylated liposomal is used together with other cancer medicines:</p><ul><li>oxaliplatin, 5-fluorouracil and leucovorin, in patients whose cancer has never been treated,</li><li>5-fluorouracil and leucovorin, in patients whose cancer has got worse despite treatment with the cancer medicine gemcitabine.</li></ul><p>Onivyde pegylated liposomal contains the active substance irinotecan.</p><p>Pancreatic cancer is rare, and Onivyde pegylated liposomal was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 9 December 2011. Further information on the orphan designation can be found here: <a href="https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-933">ema.europa.eu/medicines/human/orphan-designations/eu311933</a>.</p>